Fort L.P. Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Fort L.P. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 23.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,844 shares of the biopharmaceutical company’s stock after acquiring an additional 2,399 shares during the quarter. Fort L.P.’s holdings in Gilead Sciences were worth $933,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Morgan Stanley boosted its position in shares of Gilead Sciences by 18.3% in the 2nd quarter. Morgan Stanley now owns 10,989,872 shares of the biopharmaceutical company’s stock worth $756,765,000 after purchasing an additional 1,702,366 shares in the last quarter. Keudell Morrison Wealth Management boosted its position in shares of Gilead Sciences by 4.5% in the 3rd quarter. Keudell Morrison Wealth Management now owns 10,727 shares of the biopharmaceutical company’s stock worth $749,000 after purchasing an additional 458 shares in the last quarter. EagleClaw Capital Managment LLC boosted its position in shares of Gilead Sciences by 1.2% in the 3rd quarter. EagleClaw Capital Managment LLC now owns 42,870 shares of the biopharmaceutical company’s stock worth $2,993,000 after purchasing an additional 516 shares in the last quarter. Eagle Asset Management Inc. boosted its position in shares of Gilead Sciences by 12.4% in the 3rd quarter. Eagle Asset Management Inc. now owns 144,079 shares of the biopharmaceutical company’s stock worth $10,063,000 after purchasing an additional 15,857 shares in the last quarter. Finally, CX Institutional boosted its position in shares of Gilead Sciences by 1.4% in the 3rd quarter. CX Institutional now owns 52,044 shares of the biopharmaceutical company’s stock worth $3,635,000 after purchasing an additional 700 shares in the last quarter. Institutional investors and hedge funds own 80.16% of the company’s stock.

A number of analysts have commented on GILD shares. StockNews.com started coverage on Gilead Sciences in a research report on Thursday, March 31st. They set a “buy” rating for the company. Mizuho lowered their price target on Gilead Sciences from $81.00 to $75.00 and set a “buy” rating for the company in a research report on Tuesday, February 8th. Wells Fargo & Company reduced their price objective on Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating for the company in a research note on Tuesday, March 22nd. BMO Capital Markets assumed coverage on Gilead Sciences in a research note on Tuesday, March 8th. They set a “hold” rating and a $65.00 price objective for the company. Finally, Barclays reduced their price objective on Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating for the company in a research note on Thursday, March 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $72.67.

NASDAQ:GILD traded up $0.24 during trading hours on Wednesday, hitting $63.42. 201,900 shares of the stock were exchanged, compared to its average volume of 8,514,530. Gilead Sciences, Inc. has a 52-week low of $57.19 and a 52-week high of $74.12. The firm’s fifty day moving average price is $60.75 and its 200 day moving average price is $65.21. The company has a current ratio of 1.48, a quick ratio of 1.30 and a debt-to-equity ratio of 1.31. The company has a market cap of $79.55 billion, a P/E ratio of 17.65, a P/E/G ratio of 0.44 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILDGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.77 by $0.35. Gilead Sciences had a return on equity of 44.98% and a net margin of 16.43%. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.28 billion. During the same period in the previous year, the business earned $2.08 EPS. Gilead Sciences’s quarterly revenue was up 2.6% on a year-over-year basis. Equities analysts expect that Gilead Sciences, Inc. will post 6.62 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 29th. Shareholders of record on Wednesday, June 15th will be paid a dividend of $0.73 per share. The ex-dividend date is Tuesday, June 14th. This represents a $2.92 annualized dividend and a yield of 4.60%. Gilead Sciences’s dividend payout ratio (DPR) is currently 81.56%.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 3,634 shares of the business’s stock in a transaction that occurred on Friday, March 11th. The stock was sold at an average price of $58.24, for a total transaction of $211,644.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Profile (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.